非奈利酮联合贝前列素钠治疗糖尿病肾病的临床效果  

Clinical effect of Finelidone combined with Beprost Sodium in the treatment of diabetic nephropathy

作　　者：陈再明[1] 李晓燕 CHEN Zaiming;LI Xiaoyan(Department of Endocrinology,Puning Overseas Chinese Hospital,Guangdong Province,Puning515300,China)

机构地区：[1]广东省普宁华侨医院内分泌科,广东普宁515300

出　　处：《中国当代医药》2025年第5期71-74,79,共5页China Modern Medicine

摘　　要：目的探讨非奈利酮联合贝前列素钠治疗糖尿病肾病(DN)的临床效果。方法选取2023年1月至2024年1月普宁华侨医院的86例DN患者作为研究对象,采用随机数字表法将其分为对照组和观察组,每组均为43例。对照组采用贝前列素钠治疗,观察组采用非奈利酮片联合贝前列素钠治疗,两组患者均持续用药3个月。比较两组患者临床效果、症状改善情况、肾功能指标,以及不良反应。结果观察组总有效率高于对照组,差异有统计学意义(P<0.05);观察组肢体水肿、蛋白尿、面色苍白、乏力改善时间均短于对照组,差异有统计学意义(P<0.05);观察组尿白蛋白肌酐(UACR)、尿微量白蛋白排泄率(UAE)、24 h尿蛋白定量(24-UP)、血肌酐(SCr)均低于对照组,肾小球滤过率(GFR)高于对照组,差异有统计学意义(P<0.05);观察组空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)水平均低于对照组,差异有统计学意义(P<0.05);两组患者不良反应总发生率比较,差异无统计学意义(P>0.05)。结论非奈利酮联合贝前列素钠治疗利于缓解DN患者疾病症状,改善其肾功能与血糖指标,无明显不良反应。Objective To investigate the clinical effect of Finelidone combined with Beprost Sodium in the treatment of diabetic nephropathy(DN).Methods A total of 86 patients with DN in Puning Overseas Chinese Hospital from January 2023 to January 2024 were selected as the study objects and they were divided into control group and observation group by random number table method,with 43 cases in each group.The control group was treated with Beprost Sodium,and the observation group was treated with Finelidone Tablets combined with Beprost Sodium.Both groups were treated for 3 months.The clinical effect,symptom improvement,renal function index and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group,the difference was statistically significant(P<0.05).The improvement time of limb edema,proteinuria,pallor and fatigue in the observation group were shorter than those in the control group,the differences were statistically significant(P<0.05).Urinary albumin creatinine(UACR),urinary albumin excretion(UAE),24 h urinary protein quantification(24-UP)and serum creatinine(SCr)in observation group were lower than those in control group,and glomerular filtration rate(GFR)was higher than that in control group,the differences were statistically significant(P<0.05).The levels of fasting plasma glucose(FPG),2 h postprandial plasma glucose(2 h PG)and glycosylated hemoglobin(HbA1c)in observation group were lower than those in control group,with statistical significances(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Finelidone combined with Beprost Sodium can alleviate the symptoms of DN patients,improve renal function and blood glucose indexes,and have no obvious adverse reactions.

关 键 词：糖尿病肾病 非奈利酮 贝前列素钠 肾功能 血糖 

分 类 号：R587.2[医药卫生—内分泌]